Homepage Top Section2

The APR-246, azacitidine combination has been granted breakthrough therapy status for the treatment of myelodysplastic syndromes in patients having a susceptible TP53 mutation. Myelodysplastic syndromes are defined as

Achillion is mainly focused on the advancement of its oral small molecule complement inhibitors into late-stage development and commercialisation. The deal adds Alexion’s product portfolio with two clinical-stage

Under the deal, Atnahs will purchase global commercial rights related to AstraZeneca’s Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose

The phase III IMvigor010 study assessing Tecentriq as an adjuvant (after surgery) monotherapy treatment has not achieved its primary endpoint of disease-free survival (DFS) compared against observation in

Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or locally advanced epithelioid sarcoma sarcoma not

The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in the Chinese city in Hubei

Imfinzi is a human monoclonal antibody that binds to PD-L1 and restricts the interaction of PD-L1 with PD-1 and CD80, helping to oppose the tumour’s immune-evading tactics and

Imbruvica is already approved in Europe for chronic lymphocytic leukaemia as a monotherapy or in combination with obinutuzumab in patients who were previously untreated for their condition. The

Via its subsidiary, Merck has completed the cash tender offer to acquire all the outstanding shares of ArQule at a purchase price of $20 per share. Merck said